News | January 21, 2022
Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
Biocon has reported consolidated financial results for the period ended December 31, 2021
Biocon has reported consolidated financial results for the period ended December 31, 2021
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
This is the company’s first partnership arrangement in China
Subscribe To Our Newsletter & Stay Updated
